IL146566A0 - A pharmaceutical composition containing anti-fas antibody - Google Patents

A pharmaceutical composition containing anti-fas antibody

Info

Publication number
IL146566A0
IL146566A0 IL14656600A IL14656600A IL146566A0 IL 146566 A0 IL146566 A0 IL 146566A0 IL 14656600 A IL14656600 A IL 14656600A IL 14656600 A IL14656600 A IL 14656600A IL 146566 A0 IL146566 A0 IL 146566A0
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
composition containing
containing anti
fas antibody
fas
Prior art date
Application number
IL14656600A
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of IL146566A0 publication Critical patent/IL146566A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL14656600A 1999-05-24 2000-05-24 A pharmaceutical composition containing anti-fas antibody IL146566A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14303399 1999-05-24
PCT/JP2000/003324 WO2000071160A1 (fr) 1999-05-24 2000-05-24 Compositions medicinales contenant un anticorps anti-fas

Publications (1)

Publication Number Publication Date
IL146566A0 true IL146566A0 (en) 2002-07-25

Family

ID=15329357

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14656600A IL146566A0 (en) 1999-05-24 2000-05-24 A pharmaceutical composition containing anti-fas antibody

Country Status (19)

Country Link
US (1) US6746673B2 (tr)
EP (1) EP1180369A4 (tr)
KR (1) KR20020008197A (tr)
CN (1) CN1191861C (tr)
AU (1) AU761544C (tr)
BR (1) BR0010909A (tr)
CA (1) CA2373992A1 (tr)
CZ (1) CZ20014181A3 (tr)
HK (1) HK1042049A1 (tr)
HU (1) HUP0201333A3 (tr)
IL (1) IL146566A0 (tr)
MX (1) MXPA01012206A (tr)
NO (1) NO20015711L (tr)
NZ (1) NZ515598A (tr)
PL (1) PL352159A1 (tr)
RU (1) RU2222347C2 (tr)
TR (1) TR200103396T2 (tr)
WO (1) WO2000071160A1 (tr)
ZA (1) ZA200109575B (tr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4772299A (en) 1998-06-18 2000-01-05 Karolinska Innovations Ab Fas peptides and antibodies for modulating apoptosis
HU228957B1 (en) * 2001-07-02 2013-07-29 Aimsco Ltd Use anti-hla-antibody for production of pharmaceutical compotisions for the treatment of diseases involving prolierative immune response
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
PE20030340A1 (es) * 2001-08-28 2003-04-05 Sankyo Co Metodo para el tratamiento o prevencion de desgaste oseo
MXPA04007311A (es) * 2002-01-28 2005-05-16 Aimsco Ltd Tratamiento de ms con suero de cabra.
US6989386B2 (en) * 2002-04-30 2006-01-24 Dana-Farber Cancer Institute Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same
AU2003242265A1 (en) * 2002-06-07 2003-12-22 Sankyo Company, Limited Combined effects of therapeutic or preventive agent composition for bone breakage
US20050032807A1 (en) * 2003-08-06 2005-02-10 Rosenwald Lindsay A. Methods of treating inflammatory diseases with ammonium salts of ornitihine derivatives
GB0427568D0 (en) * 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
US8052971B2 (en) * 2005-11-21 2011-11-08 MG Biologics Oral use of specific antibodies for intestinal health
CN101092417B (zh) * 2006-06-19 2011-04-27 上海金色医药科技发展有限公司 一种叶酸类似物及用于医疗的叶酸类似物的盐
CN101820879B (zh) * 2007-10-08 2013-01-02 疟疾药物投资公司 具有柔性侧链的抗疟用化合物
EP2310412B1 (en) 2008-06-20 2018-02-21 Novartis AG Immunoglobulins with reduced aggregation
BRPI0915414A2 (pt) 2008-06-20 2021-09-08 Novartis Ag Métodos para identificar uma região propensa à agregação e uma região de ligação de macromolécula em uma proteína, bem como métodos para produzir uma variante de proteína e uma composição farmacêutica.
WO2010013498A1 (ja) * 2008-08-01 2010-02-04 学校法人聖マリアンナ医科大学 変形性関節症治療剤又は予防剤
KR20180056805A (ko) * 2009-06-04 2018-05-29 노파르티스 아게 ＩｇＧ 콘쥬게이션을 위한 자리의 확인 방법
EP2266984A1 (en) * 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis
KR101138460B1 (ko) 2009-10-12 2012-04-26 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
WO2011046309A2 (en) * 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
WO2014022817A2 (en) 2012-08-03 2014-02-06 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0021292B1 (en) * 1979-06-14 1983-03-09 The Wellcome Foundation Limited Alkoxybenzylpyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
ZA861235B (en) * 1985-03-08 1986-10-29 Univ Princeton Pyrido(2,3-d)pyrimidine derivatives
DE3603577A1 (de) * 1986-02-06 1987-08-13 Joachim K Prof Dr Seydel Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
JPH02237935A (ja) 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
US5008391A (en) * 1989-07-07 1991-04-16 Eli Lilly And Company Enantioselective synthesis of antifolates
US4996207A (en) * 1990-01-18 1991-02-26 Nair Madhavan G Three new non-polyglutamatable deazaaminopterins
WO1991010448A1 (en) 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
CA2071205C (en) 1990-01-19 2000-03-14 Peter H. Krammer Cell surface antigen associated with cellular apoptosis
CA2095518A1 (en) * 1990-11-14 1992-05-15 Jeffrey M. Blaney Specific inhibition of dihydrofolate reductase and compounds therefor
AU3276793A (en) * 1991-12-20 1993-07-28 Agouron Pharmaceuticals, Inc. Antifolate quinazolines
US5877176A (en) * 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
US5426110A (en) * 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
CA2210500A1 (en) * 1995-01-16 1996-07-25 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound - fatty acid conjugates
US6221615B1 (en) * 1995-05-12 2001-04-24 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
CA2230852A1 (en) * 1995-08-30 1997-03-06 The Regents Of The University Of California Therapy for cellular accumulation in chronic inflammatory diseases
EP0897724A4 (en) * 1996-03-19 2003-05-07 Chugai Pharmaceutical Co Ltd MEDICINE AGAINST UVEITY
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
IL123756A0 (en) * 1997-03-21 1998-10-30 Sankyo Co Humanized anti-human FAS antibody
IL123888A0 (en) * 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease

Also Published As

Publication number Publication date
ZA200109575B (en) 2003-04-30
BR0010909A (pt) 2002-02-19
CN1191861C (zh) 2005-03-09
NZ515598A (en) 2004-05-28
PL352159A1 (en) 2003-07-28
EP1180369A4 (en) 2002-07-24
HUP0201333A3 (en) 2004-11-29
EP1180369A1 (en) 2002-02-20
AU4948600A (en) 2000-12-12
TR200103396T2 (tr) 2002-04-22
HUP0201333A2 (en) 2002-08-28
US6746673B2 (en) 2004-06-08
RU2222347C2 (ru) 2004-01-27
WO2000071160A1 (fr) 2000-11-30
AU761544B2 (en) 2003-06-05
NO20015711D0 (no) 2001-11-23
CZ20014181A3 (cs) 2002-03-13
AU761544C (en) 2004-02-12
US20020103212A1 (en) 2002-08-01
CN1364090A (zh) 2002-08-14
NO20015711L (no) 2002-01-11
MXPA01012206A (es) 2002-06-21
CA2373992A1 (en) 2000-11-30
KR20020008197A (ko) 2002-01-29
HK1042049A1 (zh) 2002-08-02

Similar Documents

Publication Publication Date Title
IL146566A0 (en) A pharmaceutical composition containing anti-fas antibody
IL145177A0 (en) A pharmaceutical composition containing xenon
IL187526A0 (en) Pharmaceutical compositions containing an a?? fragment
PL351387A1 (en) Pharmaceutical composition
HUP0400644A3 (en) Pharmaceutical compositions containing aspirin
IL146632A0 (en) Pharmaceutical tablets
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
IL145632A0 (en) Pharmaceutical compounds
GB0031084D0 (en) Pharmaceutical compounds
EG23937A (en) Novel pharmaceutical
GB9916434D0 (en) Pharmaceutical compounds
GB9914255D0 (en) Pharmaceutical compounds
GB9909041D0 (en) Novel pharmaceutical
GB9903784D0 (en) Pharmaceutical compounds
EG23946A (en) Novel pharmaceutical
GB0019272D0 (en) Pharmaceutical compounds
GB2373499B (en) Pharmaceutical compounds
GB0024318D0 (en) Pharmaceutical compounds
GB0005366D0 (en) Pharmaceutical compounds
GB9923933D0 (en) Novel pharmaceutical
HU9900064V0 (en) Dispenser for pills
SI1169298T1 (sl) Framacevtske spojine
SI1252133T1 (en) Pharmaceutical compounds
GB0031579D0 (en) Pharmaceutical compounds
GB0012534D0 (en) Pharmaceutical compounds